Phase 2 study of treatment selection based on tumor thymidylate synthase expression in previously untreated patients with metastatic colorectal cancer: A trial of the ECOG ‐ACRIN Cancer Research Group (E4203)

CONCLUSIONSTS expression was prognostic: Patients with TS‐L tumors who received FOLFOX/Bev had a longer PFS than those with TS‐H tumors, along with a trend toward longer OS. Patients with TS‐H tumors did not benefit more from IROX/Bev than from FOLFOX/Bev. Cancer 2017. © 2017 American Cancer Society.

Source: Cancer - December 6, 2017 Category: Cancer & Oncology Authors: Neal J. Meropol, Yang Feng, Jean L. Grem, Mary F. Mulcahy, Paul J. Catalano, John S. Kauh, Michael J. Hall, Joel N. Saltzman, Thomas J. George, Jeffrey Zangmeister, Elena G. Chiorean, Puneet S. Cheema, Peter J. O'Dwyer, Al B. Benson Tags: Original Article Source Type: research